Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junlong Wu

Showing results (101-110 of 124) with videos related to

Pageof 13
Sort By:
BJUI Compass|July 17, 2025
Early clinical experience with the Carina robotic platform in urologic surgeryHongkai Wang, Dalong Cao, Marcio Covas Moschovas, et al.
Med (New York, N.Y.)|August 16, 2024
Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancerJian Pan, Junlong Wu, Beihe Wang, et al.
European Urology Oncology|March 19, 2022
Stereotactic Radiotherapy for Lesions Detected via <sup>68</sup>Ga-Prostate-specific Membrane Antigen and <sup>18</sup>F-Fluorodexyglucose Positron Emission Tomography/Computed Tomography in Patients with Nonmetastatic Prostate Cancer with Early Prostate-specific Antigen Progression on Androgen Deprivation Therapy: A Prospective Single-center StudyJian Pan, Yu Wei, Tingwei Zhang, et al.
JCO Precision Oncology|July 25, 2025
Genomic Landscape and Clinical Relevance in Chinese Patients With Upper Tract Urothelial CarcinomaZhi Shang, Jian Pan, Shanshan Wang, et al.
Cancer Research|February 28, 2019
Retinoic Acid-Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder CancerDalong Cao, Zihao Qi, Yangyang Pang, et al.
Molecular Oncology|October 9, 2022
The prevalence and prognosis of next-generation therapeutic targets in metastatic castration-resistant prostate cancerJian Pan, Jinou Zhao, Xudong Ni, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 7, 2026
Consolidative therapy for PSMA-avid lesions after 3 cycles of apalutamide plus androgen deprivation in metastatic hormone-sensitive prostate cancer: A prospective phase 2 single-arm trialJian Pan, Beihe Wang, Bin Zhu, et al.
Cancer Immunology, Immunotherapy : CII|December 15, 2022
Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patientsBangwei Fang, Yu Wei, Hao Zeng, et al.
Frontiers in Oncology|December 28, 2020
Prognostic Value of Local Treatment in Prostate Cancer Patients With Different Metastatic Sites: A Population Based Retrospective StudyShengming Jin, Jiaming Wei, Junjie Wang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 31, 2023
Heterogeneity of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT in metastatic castration-resistant prostate cancer: genomic characteristics and association with abiraterone responseJian Pan, Jinou Zhao, Xudong Ni, et al.
Pageof 13

Showing results (101-110 of 124) with videos related to

Sort By:
Pageof 13
BJUI Compass|July 17, 2025
Early clinical experience with the Carina robotic platform in urologic surgeryHongkai Wang, Dalong Cao, Marcio Covas Moschovas, et al.
Med (New York, N.Y.)|August 16, 2024
Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancerJian Pan, Junlong Wu, Beihe Wang, et al.
European Urology Oncology|March 19, 2022
Stereotactic Radiotherapy for Lesions Detected via <sup>68</sup>Ga-Prostate-specific Membrane Antigen and <sup>18</sup>F-Fluorodexyglucose Positron Emission Tomography/Computed Tomography in Patients with Nonmetastatic Prostate Cancer with Early Prostate-specific Antigen Progression on Androgen Deprivation Therapy: A Prospective Single-center StudyJian Pan, Yu Wei, Tingwei Zhang, et al.
JCO Precision Oncology|July 25, 2025
Genomic Landscape and Clinical Relevance in Chinese Patients With Upper Tract Urothelial CarcinomaZhi Shang, Jian Pan, Shanshan Wang, et al.
Cancer Research|February 28, 2019
Retinoic Acid-Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder CancerDalong Cao, Zihao Qi, Yangyang Pang, et al.
Molecular Oncology|October 9, 2022
The prevalence and prognosis of next-generation therapeutic targets in metastatic castration-resistant prostate cancerJian Pan, Jinou Zhao, Xudong Ni, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 7, 2026
Consolidative therapy for PSMA-avid lesions after 3 cycles of apalutamide plus androgen deprivation in metastatic hormone-sensitive prostate cancer: A prospective phase 2 single-arm trialJian Pan, Beihe Wang, Bin Zhu, et al.
Cancer Immunology, Immunotherapy : CII|December 15, 2022
Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patientsBangwei Fang, Yu Wei, Hao Zeng, et al.
Frontiers in Oncology|December 28, 2020
Prognostic Value of Local Treatment in Prostate Cancer Patients With Different Metastatic Sites: A Population Based Retrospective StudyShengming Jin, Jiaming Wei, Junjie Wang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 31, 2023
Heterogeneity of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT in metastatic castration-resistant prostate cancer: genomic characteristics and association with abiraterone responseJian Pan, Jinou Zhao, Xudong Ni, et al.
Pageof 13